Join our daily newsletter At The Bell to receive exclusive market insights
- INOVIQ (IIQ) receives a patent from the US Patent and Trademark Office, protecting its hTERT technology in cancer applications
- The patent is titled “Method of detecting cancer” and expires on March 11, 2035
- The patent claims use of the company’s telomerase antibody to resolve inconclusive cytology and detect malignant cells
- The hTERT test is an immunocytochemistry assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers
- Shares in INOVIQ are up 9.38 per cent, trading at 70 cents at 10:53 am AEST
INOVIQ (IIQ) has been granted a patent from the US Patent and Trademark Office, protecting its hTERT technology in cancer applications.
The company is issued US Patent No 11,391,738 entitled “Method of detecting cancer”, expiring March 11, 2035 and claimed use of the company’s telomerase antibody to resolve inconclusive cytology and detect malignant cells.
“This application is a continuation of US patent 10,338,072 and provides additional coverage of our hTERT assay for telomerase‐based detection of cancers other than bladder cancer, such as thyroid and breast cancer,” CEO Dr Leearne Hinch said.
The hTERT test is an immunocytochemistry assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers.
The present test is used as an adjunct to urine cytology, assisting in the diagnosis of bladder cancer.
It has been an eventful week for the company which engaged Percorso Life Sciences to provide contract sales and logistics services to accelerate the roll-out of its EXO-NET research products in the US.
Shares in INOVIQ were up 9.38 per cent, trading at 70 cents at 10:53 am AEST.
